复方苦参注射液联合化疗对结直肠癌患者临床疗效及安全性的影响  

Clinical Efficacy of Compound Kushen Injection(复方苦参注射液)Combined with Chemotherapy in Patients with Colorectal Cancer and Security Implications

作　　者：周世海[1] ZHOU Shihai(Liaoyuan Central Hospital,Liaoyuan 220400,Jilin,China)

机构地区：[1]辽源市中心医院,吉林辽源220400

出　　处：《辽宁中医杂志》2024年第12期89-92,共4页Liaoning Journal of Traditional Chinese Medicine

摘　　要：目的探讨复方苦参注射液联合化疗对结直肠癌患者免疫功能及临床疗效的影响。方法采用回顾性研究,依据不同的治疗方法将2018年1月—2023年12月辽源市中心医院肿瘤内科收治的98例结直肠癌患者分为对照组和观察组,每组49例,对照组采用化疗,观察组在对照组的基础上增加复方苦参注射液。评估两组患者近期临床疗效、治疗前后血清肿瘤标记物水平变化、生活能力[Karnofsky功能状态(Karnofsky Performance Status,KPS)评分]及治疗期间不良反应发生情况。结果治疗后,观察组的客观缓解率和疾病控制率分别为85.7%(42/49)和95.9%(47/49),明显高于对照组的63.3%(31/49)和81.6%(40/49),组间比较均差异有统计学意义(P<0.05);治疗前,两组患者血清癌胚抗原(carcinoembryonic antigen,CEA)、糖类抗原199(carbohydrate antigen 199,CA199)和糖类抗原125(carbohydrate antigen 125,CA125)水平均差异无统计学意义(P>0.05),治疗后,观察组CEA、CA199和CA125水平均低于对照组,差异具有统计学意义(P<0.05);治疗后,观察组患者的KPS分数高于对照组,组间差异具有统计学意义(P<0.05);观察组在治疗期间胃肠道不良反应发生率(69.4%,34/49)显著低于对照组(91.8%,45/49),差异具有统计学意义(P<0.05)。结论采用复方苦参注射液联合化疗治疗结直肠癌,疗效更明显,不良反应更少,该疗法能够显著提升患者生活质量,值得临床推广应用。Objective To investigate the effect of Compound Kushen Injection(复方苦参注射液)combined with chemotherapy on the clinical efficacy and safety of colorectal cancer(CRC)patients.Methods A retrospective study was conducted to divide 98 colorectal cancer patients admitted to the Department of Medical Oncology of Liaoyuan Central Hospital from January 2018 to December 2023 into control group and observation group,with 49 cases in each group.The short-term clinical efficacy,changes in serum tumor marker levels,life ability(Karnofsky Performance Status,KPS)and adverse reactions during treatment were evaluated in the two groups.Results After treatment,the objective response rate and disease control rate of the observation group were 85.7%(42/49)and 95.9%(47/49),respectively,which were significantly higher than those of the control group[63.3%(31/49)and 81.6%(40/49)],and there was a statistically significant difference between the groups(P<0.05).Before treatment,there was no statistically significant difference in the levels of serum carcinoembryonic antigen(CEA),carbohydrate antigen 199(CA199),and carbohydrate antigen 125(CA125)between the two groups of patients(P>0.05).After treatment,the levels of CEA,CA199,and CA125 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the KPS scores of the observation group were higher than those of the control group,and the difference between the groups was statistically significant(P<0.05).The incidence of gastrointestinal adverse reactions during treatment in the observation group(69.4%,34/49)was significantly lower than that in the control group(91.8%,45/49),and the difference was statistically significant(P<0.05).Conclusion The treatment of colorectal cancer with Compound Kushen Injection combined with chemotherapy has more obvious efficacy and fewer toxic side effects,which can significantly improve the quality of life of patients and is worthy of clinical application.

关 键 词：结直肠癌 复方苦参注射液 恶性肿瘤 化疗 胃肠道反应 

分 类 号：R273[医药卫生—中西医结合]